Serum paraoxonase activities, nitric oxide, and malondialdehyde levels are altered in patients with primary fibromyalgia syndrome

Basit Öğe Kaydı
dc.contributor.authorAtamer, Yildiz
dc.contributor.authorSarac, Serdar
dc.contributor.authorAsik, Hatice Kubra
dc.contributor.authorSahbaz, Tugba
dc.date.accessioned2024-03-13T10:30:52Z
dc.date.available2024-03-13T10:30:52Z
dc.date.issued2023
dc.departmentİstanbul Beykent Üniversitesien_US
dc.description.abstractBackgroundFibromyalgia patients who are exposed to extreme oxidative stress may face more severe clinical features or oxidative stress may be increased by the severity of the disease.AimThe purpose of these investigation were to determine serum paraoxonase activities (PON-1) and nitric oxide (NO) activities and malondialdehyde (MDA) level in fibromyalgia and whether there were any associations between these enzymes activities, MDA level, and clinical parameters.MethodsThe study groups were consisted of 30 primer fibromyalgia patients and 30 healthy subjects. Clinical findings, pain severity, functional disability, general health status, anxiety, and depression assessed, and serum PON-1 activity, MDA, and NO levels were measured.ResultsThe primer fibromyalgia group had significantly higher MDA, low density lipoprotein-cholesterol (LDL-C), and decreased PON-1 activity, NO, and high density lipoprotein-cholesterol (HDL-C) with respect to controls. The paraoxonase activity was negatively correlated with MDA, LDL-C, Visual Analog Scale (VAS), Fibromyalgia Impact Questionnaire score (FIQ score), tender point score, age, and BDI score, while positively correlated with NO and HDL-C. MDA level was positively correlated with VAS, FIQ score, tender point score, age, and negatively correlated with NO level.ConclusionThese results suggest that FMS patients have an alteration in levels of MDA, NO, and PON-1 activities. We think that impaired oxidant/antioxidant status may affect the symptoms of the disease. Also, they may be of importance in the complex physiopathologic mechanism behind the development of FMS.en_US
dc.identifier.doi10.1007/s11845-023-03280-2
dc.identifier.endpage2547en_US
dc.identifier.issn0021-1265
dc.identifier.issn1863-4362
dc.identifier.issue5en_US
dc.identifier.pmid36689069en_US
dc.identifier.scopus2-s2.0-85146694384en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2541en_US
dc.identifier.urihttps://doi.org/10.1007/s11845-023-03280-2
dc.identifier.urihttps://hdl.handle.net/20.500.12662/3570
dc.identifier.volume192en_US
dc.identifier.wosWOS:000919705900002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofIrish Journal Of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLipoproteinsen_US
dc.subjectMalondialdehydeen_US
dc.subjectNitric oxideen_US
dc.subjectPrimary Fibromyalgiaen_US
dc.subjectParaoxonaseen_US
dc.titleSerum paraoxonase activities, nitric oxide, and malondialdehyde levels are altered in patients with primary fibromyalgia syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu